463Indexed trials
mesh condition
Attention Deficit Disorder with Hyperactivity
Intelligence
Attention Deficit Disorder with Hyperactivity intelligence: 463 indexed trials, 57 recruiting studies, 283 sponsors across 40 countries.
57Recruiting
283Sponsors
40Countries
Leading sponsors
Massachusetts General Hospital182 recruiting
Shire130 recruiting
National Taiwan University Hospital90 recruiting
Eli Lilly and Company80 recruiting
Duke University81 recruiting
Children's Hospital Medical Center, Cincinnati70 recruiting
National Institute of Mental Health (NIMH)70 recruiting
Karolinska Institutet70 recruiting
Supernus Pharmaceuticals, Inc.60 recruiting
Hospital de Clinicas de Porto Alegre50 recruiting
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.52 recruiting
Florida International University50 recruiting
Geographic activity
United States204trials
Israel27trials
France22trials
Taiwan19trials
China18trials
Canada17trials
Sweden12trials
United Kingdom12trials
Brazil10trials
Spain9trials
Turkey (Türkiye)9trials
Germany8trials
Leading interventions
Methylphenidate18trials
Atomoxetine10trials
methylphenidate5trials
Behavioral Parent Training5trials
atomoxetine5trials
Concerta4trials
200mg SPN-8123trials
Lisdexamfetamine3trials
Atomoxetine Hydrochloride3trials
Atomoxetine hydrochloride3trials
Treatment as usual3trials
Behavioral Parent Training (BPT)2trials
Methodology note
This entity is derived from structured ClinicalTrials.gov conditions and/or MeSH normalization. Counts reflect the current NeuroRisk indexed corpus and are not guaranteed exhaustive global totals.